Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adriano Chio

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 24, 2024
The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trialsAngela Genge, Jesse M Cedarbaum, Jeremy Shefner, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 9, 2019
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trialJesus S Mora, Angela Genge, Adriano Chio, et al.
Nature Communications|August 17, 2023
Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosisJessica Mandrioli, Roberto D'Amico, Elisabetta Zucchi, et al.
Neurology|March 10, 2019
Revised Airlie House consensus guidelines for design and implementation of ALS clinical trialsLeonard H van den Berg, Eric Sorenson, Gary Gronseth, et al.
Journal of Neurology|August 16, 2015
C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson's disease complicated by psychosis or dementia in a Sardinian populationAntonino Cannas, Paolo Solla, Giuseppe Borghero, et al.
Neurology|October 6, 2017
Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trialsRuben P A van Eijk, Ashley R Jones, William Sproviero, et al.
Brain Communications|October 28, 2021
<i>SCFD1</i> expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressedAlfredo Iacoangeli, Isabella Fogh, Sashika Selvackadunco, et al.
The Lancet. Neurology|October 11, 2014
Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling studyAmmar Al-Chalabi, Andrea Calvo, Adriano Chio, et al.
JAMA Neurology|March 24, 2025
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical TrialJeremy M Shefner, Merit E Cudkowicz, Angela Genge, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 12, 2025
Hospitalizations as an outcome measure in COURAGE-ALSStacy A Rudnicki, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 24, 2024
The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trialsAngela Genge, Jesse M Cedarbaum, Jeremy Shefner, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 9, 2019
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trialJesus S Mora, Angela Genge, Adriano Chio, et al.
Nature Communications|August 17, 2023
Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosisJessica Mandrioli, Roberto D'Amico, Elisabetta Zucchi, et al.
Neurology|March 10, 2019
Revised Airlie House consensus guidelines for design and implementation of ALS clinical trialsLeonard H van den Berg, Eric Sorenson, Gary Gronseth, et al.
Journal of Neurology|August 16, 2015
C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson's disease complicated by psychosis or dementia in a Sardinian populationAntonino Cannas, Paolo Solla, Giuseppe Borghero, et al.
Neurology|October 6, 2017
Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trialsRuben P A van Eijk, Ashley R Jones, William Sproviero, et al.
Brain Communications|October 28, 2021
<i>SCFD1</i> expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressedAlfredo Iacoangeli, Isabella Fogh, Sashika Selvackadunco, et al.
The Lancet. Neurology|October 11, 2014
Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling studyAmmar Al-Chalabi, Andrea Calvo, Adriano Chio, et al.
JAMA Neurology|March 24, 2025
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical TrialJeremy M Shefner, Merit E Cudkowicz, Angela Genge, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 12, 2025
Hospitalizations as an outcome measure in COURAGE-ALSStacy A Rudnicki, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Pageof 8